Researchers evaluated data from 25 different randomized clinical trials, sharing their findings virtually at EuroPCR 2021. 

The two-year rates of all-cause mortality or disabling stroke were 4.3% for TAVR patients and 6.3% for SAVR patients.

Abbott’s transcatheter tricuspid valve repair system is a safe and effective approach to treating tricuspid regurgitation in heart patients with few other options, according to data published in The Lancet.

With minimally invasive structural procedures crowding out their surgical counterparts, how are physicians and hospitals preparing for the new reality? 

Corindus Vascular Robotics’ CorPath GRX system—the world’s only FDA-approved and CE-marked robotic platform for percutaneous coronary intervention (PCI) and peripheral vascular intervention—was used in the first-ever live transmission of a robotic PCI in Europe during this year's EuroPCR congress.

Three-year results of the BIO-RESORT study, presented at EuroPCR this week in Paris, put Biotronik’s ultrathin Orsiro stent ahead of two other competitors in terms of target lesion failure and revascularization.

The European Association of Percutaneous Cardiovascular Interventions (EAPCI) has published a clinical guidance statement regarding the use of intra-coronary imaging (IC), sharing the document during its EuroPCR Annual Meeting, May 21-24 in Paris.

Results from the TRILUMINATE study, presented this week at EuroPCR 2019 in Paris, suggest Abbott’s minimally invasive tricuspid valve repair system is an effective solution for patients with structural heart disease, reducing the severity of tricuspid regurgitation (TR) in more than 85% of test cases.